BLACK WEEKSFlakonai −15% · rinkiniai −10% · kita −5%su koduNemokamas siuntimas Vokietijoje nuo €200

Šis puslapis išverstas automatiškai ir jame gali būti klaidų. Ar lietuvių kalba yra jūsų gimtoji? Mielai sulauksime jūsų atsiliepimų ir pataisymų.Siųsti atsiliepimą

The Peptide Desk The Peptide Desk
Torasemid, produkto nuotrauka
Medication

Torasemid

Medication

  • Siunčiame iš Vokietijos

Užsakymas

Vieneto kaina - Nemokamas siuntimas Vokietijoje nuo 200 € Black Weeks metu
  • DHL su sekimu
  • Diskreti pakuotė

4.6 iš 5 TrustpilotAtsiliepimų: 73

Trumpai

Torasemid skaičiais

Pagrindiniai rodikliai iš mūsų žinyno. Vilkite tašką kreive, kad pamatytumėte, kiek lieka po vienos dozės, pagal skaičiavimą.

Visas žinyno įrašas

How long does it stay in the body?

Share left after one dose, calculated with a half-life of ~3.5 hours

Half-life ~3.5 hours
After 7 hours: 25 %
Hour 445 %Hour 725 %Hour 1111.3 %Hour 182.8 %

Simplified model without an absorption phase, half-life from the TPD lexicon. The lexicon gives 3 to 4 hours, we calculate with the middle.

Half-life

about3to4hours

duration 6 to 8 hours

Class
Loop diureticNKCC2 inhibitor
Use
Oral1x daily in the morning
Sizes
10 mg1 size in the shop

Produktui Torasemid laboratorinės analizės dar nėra. Balsuoti už taiUžsakykite tyrimą, mes apmokame pusęVisos laboratorinės analizės

Žinios

Viskas apie Torasemid

FAQ

Dažnai užduodami klausimai

Šaltiniai kiekvienam atsakymui: žinyno įrašas

Dar turite klausimų?

Parašykite mums, mūsų komanda jums padės.

Is torsemide approved?

Yes. ChEMBL lists torsemide with phase 4 as the highest phase and first approval in 1993. ClinicalTrials.gov lists 56 trials with torsemide, as of 26 October 2026.

What did TRANSFORM-HF show?

2,859 patients received torsemide or furosemide after a hospital stay for heart failure. 26.1 versus 26.2 percent died, without difference. Death or hospital stay within 12 months did not differ significantly either (47.3 versus 49.3 percent).

How does absorption differ from furosemide?

Torsemide has a bioavailability of about 80 percent in healthy people, furosemide 26 to 65 percent. In heart failure the peak level was reached after 1.1 instead of 2.4 hours. Absorption varied less.

Why did earlier trials see an advantage?

An open trial with 234 patients found fewer hospital stays for heart failure (17 versus 32 percent). The TORIC observation with 1,377 patients saw lower mortality (2.2 versus 4.5 percent) but was not randomised. The larger randomised trial did not confirm this.

What about potassium?

In TORIC 12.9 percent on torsemide had low potassium at the end, 17.9 percent on furosemide or other diuretics. The groups were not randomised.

Do liver and kidney matter?

Torsemide is mainly broken down in the liver, only about 20 percent appear unchanged in the urine. In liver disease clearance fell to about half. In kidney failure total clearance stayed largely the same according to the review.

Susiję

Susiję produktai